Gilead Sciences, Inc. announced today that Jacqueline K. Barton, Ph.D., has been appointed to the company’s Board of Directors. She previously served on Gilead’s Scientific Advisory Board from 1989 to 2007.
Dr. Barton is the John G. Kirkwood and Arthur A. Noyes Professor of Chemistry and Norman Davidson Leadership Chair of the Division of Chemistry and Chemical Engineering at the California Institute of Technology, where she has been a faculty member for nearly 30 years. She served on the Board of Directors of the Dow Chemical Company from 1993 to 2017, and currently is a member of the Materials Science Advisory Committee of DowDuPont, Inc. She founded and served on the Board of GeneOhm Sciences, Inc., a molecular diagnostic company acquired by Becton Dickinson and Company. She is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. In 2011, Dr. Barton received the National Medal of Science for her discovery of new chemistry of the DNA helix.
“We are very pleased to welcome Jacqueline Barton to the Board of Directors of Gilead Sciences,” said John Milligan, Ph.D., President and Chief Executive Officer, Gilead Sciences. “Jackie is one of the most decorated chemists in America and was awarded the Priestley Medal from the American Chemical Society, its highest honor. Her deep knowledge of scientific discovery in both academic and industry settings will help guide our long-term strategy as Gilead continues to translate science into better solutions for patients.”
Source: Gilead Sciences
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
